Postgraduate medicine
-
Postgraduate medicine · Nov 2024
Randomized Controlled TrialPentoxifylline improves anemia through its novel effect on hypoxia-inducible factor-2 alpha in hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial.
This randomized, double-blind, placebo-controlled clinical trial aimed to prospectively examine the effect of pentoxifylline (PTX) on hypoxia-inducible factor-2 alpha (HIF-2α) and its role in controlling anemia in hemodialysis (HD) patients. ⋯ Clinicaltrials.gov, February 2023, registry number: NCT05708248.
-
Postgraduate medicine · Aug 2024
Randomized Controlled Trial Multicenter StudyEvaluation of the use of telemedicine in pediatric intensive care units: a cluster-randomized trial.
Telemedicine has shown promising results, allowing specialists to provide rapid and effective care in remote locations. However, to our knowledge, current evidence is not robust enough to prove the effectiveness of this tool. This cluster-randomized trial (CRT) aimed to evaluate the impact of telemedicine on clinical care indicators in pediatric intensive care units (PICUs). ⋯ ClinicalTrials.gov NCT05260710 and ReBEC - RBR-7×j4wyp.
-
Postgraduate medicine · Jun 2024
Randomized Controlled TrialWearable monitoring device based on an internet management platform improves metabolic parameters in type 2 diabetes patients: a prospective pilot study.
This pilot study aimed to prospectively investigate the effects of a wearable monitoring device, based on an Internet management platform, on the comprehensive management of type 2 diabetes mellitus (T2DM) patients. ⋯ NCT04973644.
-
Postgraduate medicine · May 2024
Randomized Controlled TrialDaridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Appraise the evidence for daridorexant 50 mg and 25 mg versus placebo when treating chronic insomnia disorder in terms of number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). ⋯ Daridorexant 50 mg and 25 mg have a favorable benefit-risk ratio over 3 months. Daridorexant 50 mg demonstrated more robust (lower) NNT estimates versus placebo than daridorexant 25 mg.
-
Postgraduate medicine · Apr 2023
Randomized Controlled TrialPredictive value of arterial blood lactate to serum albumin ratio for in-hospital mortality of patients with community-acquired pneumonia admitted to the Intensive Care Unit.
To investigate the predictive value of the arterial blood lactate to serum albumin ratio (LAR) on in-hospital mortality of patients with community-acquired pneumonia (CAP) admitted to the Intensive Care Unit (ICU). ⋯ LAR could predict in-hospital mortality of patients with CAP admitted to ICU independently as a readily accessible biomarker. The nomogram that included LAR with other independent factors performed well in predicting in-hospital mortality.